Monte Rosa Therapeutics Files Routine 8-K on Jan 8, 2024

Ticker: GLUE · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1826457

Monte Rosa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyMonte Rosa Therapeutics, Inc. (GLUE)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, 8-K, emerging-growth-company

TL;DR

**GLUE filed a routine 8-K, confirming its emerging growth company status and Nasdaq listing.**

AI Summary

Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. This filing indicates that the company is an emerging growth company and its common stock, with a $0.0001 par value per share, is traded on The Nasdaq Global Select Market under the symbol GLUE. For investors, this filing is a routine disclosure, confirming the company's status and listing, which is important for transparency but doesn't reveal new material financial or operational changes.

Why It Matters

This filing is a standard disclosure, confirming Monte Rosa Therapeutics' status as an emerging growth company and its Nasdaq listing, which is important for regulatory transparency.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain information that would significantly alter the company's risk profile.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes to Monte Rosa Therapeutics, Inc. (GLUE). Further due diligence would focus on other filings for operational or financial updates.

Key Numbers

  • $0.0001 — par value per share (the stated value of each common stock share)

Key Players & Entities

  • Monte Rosa Therapeutics, Inc. (company) — the registrant filing the 8-K
  • GLUE (company) — trading symbol for Monte Rosa Therapeutics, Inc.
  • The Nasdaq Global Select Market (company) — exchange where GLUE common stock is registered
  • $0.0001 (dollar_amount) — par value per share of common stock
  • January 8, 2024 (date) — date of earliest event reported and filing date

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is MONTE ROSA THERAPEUTICS, INC.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 8, 2024.

What is the trading symbol for Monte Rosa Therapeutics, Inc. common stock?

The trading symbol for Monte Rosa Therapeutics, Inc. common stock is GLUE.

Which exchange is Monte Rosa Therapeutics, Inc. common stock registered on?

Monte Rosa Therapeutics, Inc. common stock is registered on The Nasdaq Global Select Market.

Is Monte Rosa Therapeutics, Inc. considered an emerging growth company according to this filing?

Yes, Monte Rosa Therapeutics, Inc. indicates by check mark that it is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-01-08 07:47:06

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On January 8, 2024 Monte Rosa Therapeutics, Inc. issued a press release titled “Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024” and provided a corporate update in conjunction with its participation at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The press release and presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated January 8, 2024. 99.2 J.P. Morgan Healthcare Conference presentation furnished by Monte Rosa Therapeutics, Inc. on January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: January 8, 2024 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.